Full Press Release Details
Supernus to Attend FBR Healthcare Conference on September 9th
ROCKVILLE, Md., August 27, 2015 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company s management will be hosting investor meetings at the FBR Second Annual Healthcare Conference.
Date: Wednesday, September 9th
Place: Four Seasons Hotel, Boston
Investors interested in arranging a meeting with the Company s management during this conference should contact the conference coordinator.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of impulsive aggression in patients with ADHD in conjunction with standard ADHD treatment and SPN-812 for ADHD.
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.